Davita Inc vs T-Mobile Us Inc — how do they compare? Davita Inc trades at $178.74 (market cap $11.38B), while T-Mobile Us Inc trades at $177.1 (market cap $191.56B). The key difference: T-Mobile Us Inc is far larger — about 16.8× Davita Inc's market cap, and T-Mobile Us Inc pays a 2.28% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | TMUS | |
|---|---|---|
Market Cap | $11.38B | $191.56B |
Sector | Health | Media |
52-Week High | $240.96 | $259.01 |
52-Week Low | $103.87 | $167.65 |
Enterprise Value | $24.10B | $308.17B |
Dividend Yield | — | 2.28% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
T-Mobile US (TMUS) trades at $178.16, up 0.55% with neutral technical signals. The stock shows strong fundamentals with revenue growth from $81.4B in 2024 to $88.3B in 2025 and robust profitability (net margin 11.45%). Recent Q2 2026 earnings beat expectations with $2.99 EPS versus $2.59 estimate. The company completed a $2.9B spectrum sale to Grain Management in August 2026, enhancing cash position. Analyst consensus remains strongly bullish with 44 buy ratings and $233.20 price target, representing 31% upside potential.
TMUS presents compelling growth prospects with expanding broadband momentum and consistent earnings beats, though faces competitive pressure from SpaceX's Starlink mobile ambitions. The stock trades at reasonable valuations (P/E 18.68, EV/EBITDA 9.55) with strong institutional support. Key risks include wireless market saturation and technological disruption from new entrants. Current levels offer attractive entry point for long-term investors given the significant analyst upside and dividend growth potential.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →